₹3445.0
-1.48% today
· 30d -4.31%
as of 2026-11-09
Price · Daily Candles
“Sanofi India: Strong Q1 profit growth overshadowed by volatile share price and FII retreat.”
Sanofi India posted impressive headline growth in Q1 2026, with net profit up 35.6% YoY to ₹68 Cr on a 32.79% revenue increase. Despite an attractive dividend yield of 1.16%, its current PE of 41.56, coupled with a 9.35% price decline over the last year, hints at investor caution. Analyst coverage remains thin, with only one analyst providing a target of ₹5855.
BULL CASE
+Q1 2026 revenue surged 32.79% YoY to ₹229 Cr, while net profit grew 35.6% YoY to ₹68 Cr.
+Operating profit increased 36.42% YoY to ₹94 Cr in Q1 2026, with OPM improving by 1.28 percentage points.
+The company maintains a high level of promoter holding at 71.27% as of March 2026.
+DII holding increased by 0.24% QoQ to 17.57% in Q1 2026, indicating domestic institutional confidence.
+The profitability score is 'HIGH' at 100, reflecting strong operational efficiency.
BEAR CASE
−The stock price has fallen 9.35% over the past year and remains 21.27% off its 52-week high of ₹5894.5.
−FIIs reduced their stake by 0.07% QoQ in Q1 2026, bringing their total holding to 2.76%.
−The PE ratio of 41.56 is higher than peers like PFIZER (29.39) and MARKSANS (30.34).
−The ML model indicates weak growth potential for Free Cash Flow (FCF) in the near term, with a rank of 0.255 for recent 2-year FCF growth.
−Technical indicators like MACD and RSI(14) are currently neutral, with RSI showing a weak signal at 47.74.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-09-30
REVENUE
₹263 Cr
+12.48% YoY
NET PROFIT
₹77 Cr
+21.78% YoY
OPM
39.66%
+2.52pp YoY
EPS
₹33.26
PE 41.56
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-2.0%, h2=-0.2%, h3=+0.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Sanofi India, with a PE of 41.56, trades at a premium to peers like Pfizer (PE 29.39) and Marksans (PE 30.34), but offers a competitive ROCE compared to Rubicon (ROCE 40.26) and Corona (ROCE 35.68).
PEERPEROCE %
SANOFICONR41.56—
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
56
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
UNDERPERFORMER
20
Valuation
FAIR
40
Growth
STEADY
52
Profitability
HIGH
95
Technicals
WEAK
40
Risk
LOW
88
Key Stats
TTM PE
41.56
P/B
27.92
52W HIGH
₹5255.0
OFF HIGH
-34.44%
DIV YIELD
1.16%
MKT CAP
₹7969 Cr
◉ Active Signals
MACDNeutral31.6562
RSI(14)Neutral44.88
Near 52W LowBearish8.74
Street Consensus
1 analyst₹5855.0
mean target
Low ₹5855.0Now ₹3445.0High ₹5855.0
⧉ Strategy Fit 🔒